The Kelch-like erythroid-associated protein 1 (Keap1)–NF-E2-related factor 2 (Nrf2) signaling pathway is the subject of several clinical trials evaluating the effects of Nrf2 activation on the prevention of cancer and diabetes and the treatment of chronic kidney disease and multiple sclerosis. This evidence concerns the gene KEAP1 and diabetes mellitus.